45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
83,779
Insurances with rates
48
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 103958918-2215111 | 69866-1030-05 - autologous cultured chondrocytes 1 | $572,571 | $309,188 | — | — | 4 |
| 103958918-2215111 | 69866-1030-05 - autologous cultured chondrocytes 1 | $572,571 | $188,948 | — | — | 9 |
| 103958919-2215111 | 69866-1030-08 - autologous cultured chondrocytes 1 | $572,571 | $309,188 | — | — | 4 |
| 103958919-2215111 | 69866-1030-08 - autologous cultured chondrocytes 1 | $572,571 | $188,948 | — | — | 9 |
| 102534551-2215105 | 71336-1001-01 - givosiran 189 mg/mL Soln | $524,940 | $283,468 | — | — | 4 |
| 102534551-2215105 | 71336-1001-01 - givosiran 189 mg/mL Soln | $524,940 | $173,230 | — | — | 9 |
| 51905029-2215107 | 30237-8900-06 - sipuleucel-T - Susp | $499,253 | $269,597 | — | — | 4 |
| 51905029-2215107 | 30237-8900-06 - sipuleucel-T - Susp | $499,253 | $164,753 | — | — | 9 |
| 1279402-2215105 | 00003-2328-22 - ipilimumab Soln | $458,745 | $247,722 | — | — | 4 |
| 1279402-2215105 | 00003-2328-22 - ipilimumab Soln | $458,745 | $151,386 | — | — | 9 |
| 106410809-2124721 | 00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln | $418,829 | $226,167 | — | — | 4 |
| 106410809-2124721 | 00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln | $418,829 | $138,213 | — | — | 9 |
| 1286149-2215105 | 54396-0801-01 - pegloticase Soln | $375,822 | $202,944 | — | — | 4 |
| 1286149-2215105 | 54396-0801-01 - pegloticase Soln | $375,822 | $124,021 | — | — | 9 |
| 95367892-2215105 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $375,822 | $202,944 | — | — | 4 |
| 95367892-2215105 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $375,822 | $124,021 | — | — | 9 |
| 1282361-2215105 | 57665-0002-02 - pegaspargase 3750. Soln | $343,745 | $185,622 | — | — | 4 |
| 1282361-2215105 | 57665-0002-02 - pegaspargase 3750. Soln | $343,745 | $113,436 | — | — | 9 |
| 1282362-2215105 | 54482-0301-01 - pegaspargase 3750. Soln | $343,745 | $185,622 | — | — | 4 |
| 1282362-2215105 | 54482-0301-01 - pegaspargase 3750. Soln | $343,745 | $113,436 | — | — | 9 |
| 99090561-2215105 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $343,745 | $185,622 | — | — | 4 |
| 99090561-2215105 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $343,745 | $113,436 | — | — | 9 |
| 94990000-2215105 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $332,470 | $179,534 | — | — | 4 |
| 94990000-2215105 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $332,470 | $109,715 | — | — | 9 |
| 102525788-2215105 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $316,059 | $170,672 | — | — | 4 |
| 102525788-2215105 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $316,059 | $104,299 | — | — | 12 |
| 96694815-2215105 | 50242-0150-01 - ocrelizumab 300 mg/10 mL Soln | $264,984 | $143,091 | — | — | 4 |
| 96694815-2215105 | 50242-0150-01 - ocrelizumab 300 mg/10 mL Soln | $264,984 | $87,445 | — | — | 12 |
| 105646369-2215105 | 00078-0734-61 - canakinumab 150 mg/mL Soln | $244,250 | $131,895 | — | — | 4 |
| 105646369-2215105 | 00078-0734-61 - canakinumab 150 mg/mL Soln | $244,250 | $80,603 | — | — | 9 |
| 95380079-2168371 | 00169-7208-01 - coagulation factor VIIa 8000 mcg ( | $230,634 | $124,543 | — | — | 4 |
| 95380079-2168371 | 00169-7208-01 - coagulation factor VIIa 8000 mcg ( | $230,634 | $76,109 | — | — | 9 |
| 100575164-2215105 | 47335-0177-95 - tildrakizumab 100 mg/mL Soln | $220,659 | $119,156 | — | — | 4 |
| 100575164-2215105 | 47335-0177-95 - tildrakizumab 100 mg/mL Soln | $220,659 | $72,817 | — | — | 9 |
| 101891901-2215107 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $217,934 | $117,685 | — | — | 4 |
| 101891901-2215107 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $217,934 | $71,918 | — | — | 9 |
| 99247005-2215105 | 75987-0130-15 - teprotumumab trbw 500 mg Powder | $213,987 | $115,553 | — | — | 4 |
| 99247005-2215105 | 75987-0130-15 - teprotumumab trbw 500 mg Powder | $213,987 | $70,616 | — | — | 9 |
| 1279159-2215106 | 63004-7731-01 - corticotropin 400. Soln | $209,300 | $113,022 | — | — | 4 |
| 1279159-2215106 | 63004-7731-01 - corticotropin 400. Soln | $209,300 | $69,069 | — | — | 9 |
| 95048080-2215105 | 47783-0101-01 - ecallantide 10 mg/mL Soln | $198,772 | $107,337 | — | — | 4 |
| 95048080-2215105 | 47783-0101-01 - ecallantide 10 mg/mL Soln | $198,772 | $65,595 | — | — | 9 |
| 101883920-2215107 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $185,415 | $100,124 | — | — | 4 |
| 101883920-2215107 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $185,415 | $61,187 | — | — | 9 |
| 1287035-2215107 | 76128-0155-75 - porfimer 75. mg REC Injection | $172,812 | $93,319 | — | — | 4 |
| 1287035-2215107 | 76128-0155-75 - porfimer 75. mg REC Injection | $172,812 | $57,028 | — | — | 12 |
| 102917747-2215107 | 72493-0103-03 - mitoMYcin 40 mg Kit | $166,874 | $90,112 | — | — | 4 |
| 102917747-2215107 | 72493-0103-03 - mitoMYcin 40 mg Kit | $166,874 | $55,068 | — | — | 9 |
| 1287179-2215105 | 57894-0060-03 - ustekinumab Soln | $166,235 | $89,767 | — | — | 4 |
| 1287179-2215105 | 57894-0060-03 - ustekinumab Soln | $166,235 | $54,858 | — | — | 9 |
Showing top 50 of 83,779 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.